In conclusion, this study demonstrates the promising efficacy of combining atezolizumab, bevacizumab, pemetrexed and cisplatin/carboplatin in EGFR‐mutated NSCLC patients who progressed on TKI therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.